Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

Retrovirology

Volumn 5, Issue , 2008, Pages

  Rhee, Soo Yon ^a   Liu, Tommy F ^a   Kiuchi, Mark ^a   Zioni, Rafael ^a   Gifford, Robert J ^a   Holmes, Susan P ^b   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; ELVITEGRAVIR; GLUTAMIC ACID; GLUTAMINE; GLYCINE; INTEGRASE; INTEGRASE INHIBITOR; ISOLEUCINE; LEUCINE; METHIONINE; POL PROTEIN; PROTEINASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; SERINE; THREONINE; VALINE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EXPOSURE; ENTROPY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PROTEIN DOMAIN; VIRAL GENETICS; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION; AMINO ACID SEQUENCE; ANIMAL; ANIMAL DISEASE; CHEMISTRY; DNA SEQUENCE; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR GENETICS; PAN TROGLODYTES; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANIMALS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PAN TROGLODYTES; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 52749086245     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-74     Document Type: Article

References (60)

1. Brown P Integration Retroviruses Cold Spring Harbor Laboratory Press Coffin J, Hughes S, Varmus H 1997 161-205 http://www.ncbi.nlm.nih.gov/ books/bv.fcgi?rid=rv.chapter.1526
2. Craigie R HIV integrase, a brief overview from chemistry to therapeutics J Biol Chem 2001, 276:23213-23216 11346660
3. Chiu TK Davies DR Structure and function of HIV-1 integrase Curr Top Med Chem 2004, 4:965-977 15134551
4. Pommier Y Johnson AA Marchand C Integrase inhibitors to treat HIV/AIDS Nat Rev Drug Discov 2005, 4:236-248 15729361
5. Chen JC Krucinski J Miercke LJ Finer-Moore JS Tang AH Leavitt AD Stroud RM Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding Proc Natl Acad Sci USA 2000, 97:8233-8238 26930 10890912
6. Wang JY Ling H Yang W Craigie R Structure of a two-domain fragment of HIV-1 integrase: Implications for domain organization in the intact protein Embo J 2001, 20:7333-7343 125787 11743009
7. Goldgur Y Craigie R Cohen GH Fujiwara T Yoshinaga T Fujishita T Sugimoto H Endo T Murai H Davies DR Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design Proc Natl Acad Sci USA 1999, 96:13040-13043 23896 10557269
8. Semenova EA Marchand C Pommier Y HIV-1 integrase inhibitors: Update and perspectives Adv Pharmacol 2008, 56:199-228 18086413
9. Lataillade M Chiarella J Kozal MJ Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance Antivir Ther 2007, 12:563-570 17668566
10. Huang X Zhang J Methods for comparing a DNA sequence with a protein sequence Comput Appl Biosci 1996, 12:497-506 9021268
11. Leitner T Korber B Daniels M Calef C Foley B HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005 HIV Sequence Compendium Los Alamos National Laboratories 2005 http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/ 2005compendium.html
12. Shenkin PS Erman B Mastrandrea LD Information-theoretical entropy as a measure of sequence variability Proteins 1991, 11:297-313 1758884
13. Rhee SY Liu TF Holmes SP Shafer RW HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation PLoS Comput Biol 2007, 3:e87 1866358 17500586
14. Benjamini Y Hochberg Y Controlling the false discovery rate: A practical and powerful approach to multiple testing J R Stat Soc Ser B 1995, 57:289-300
15. Sotriffer CA Ni H McCammon JA Active site binding modes of HIV-1 integrase inhibitors J Med Chem 2000, 43:4109-4117 11063607
16. Lee DJ Robinson WE Jr Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors Antimicrob Agents Chemother 2006, 50:134-142 1346808 16377678
17. Zargarian L Benleumi MS Renisio JG Merad H Maroun RG Wieber F Mauffret O Porumb H Troalen F Fermandjian S Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA J Biol Chem 2003, 278:19966-19973 12626494
18. Lu R Limon A Ghory HZ Engelman A Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase J Virol 2005, 79:2493-2505 546573 15681450
19. Jones G Ledford R Yu F Miller M Tsiang M McColl D Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303) [abstract 627] 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA 2007 February 25-28 2007.
20. Mccoll D Fransen S Gupta S Parking N Margot N Chuck S Cheng A Miller M Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase II study of elvitegravir (GS-9137) [abstract 9] Antivir Ther 2007:12
21. Hazuda D Miller M Nguyen B Zhao J Resistance to the HIV integrase inhibitor raltegravir: Analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 [abstract 8] Antivir Ther 2007:12
22. Cherepanov P Ambrosio AL Rahman S Ellenberger T Engelman A Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 Proc Natl Acad Sci USA 2005, 102:17308-17313 1297672 16260736
23. Lu R Ghory HZ Engelman A Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase J Virol 2005, 79:10356-10368 1182625 16051828
24. Merck Isentress Package Insert 2007
25. Goethals O Clayton R Wagemans E Van Gindere M Cummings M Geluykens P Dockx K Smits V Meersseman G Jochmans D Hallenberger S Hertogs K Resistance mutations in HIV-1 selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors [abstract 9] Antivr Ther 2008, 13(Suppl 3):A11
26. Harper AL Sudol M Katzman M An amino acid in the central catalytic domain of three retroviral integrases that affects target site selection in nonviral DNA J Virol 2003, 77:3838-3845 149511 12610159
27. Diamond TL Bushman FD Division of labor within human immunodeficiency virus integrase complexes: Determinants of catalysis and target DNA capture J Virol 2005, 79:15376-15387 1316026 16306609
28. Espeseth AS Felock P Wolfe A Witmer M Grobler J Anthony N Egbertson M Melamed JY Young S Hamill T Cole JL Hazuda DJ HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase Proc Natl Acad Sci USA 2000, 97:11244-11249 17185 11016953
29. Marchand C Neamati N Pommier Y In vitro human immunodeficiency virus type 1 integrase assays Methods Enzymol 2001, 340:624-633 11494874
30. Hazuda DJ Felock P Witmer M Wolfe A Stillmock K Grobler JA Espeseth A Gabryelski L Schleif W Blau C Miller MD Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 2000, 287:646-650 10649997
31. Hazuda DJ Anthony NJ Gomez RP Jolly SM Wai JS Zhuang L Fisher TE Embrey M Guare JP Jr Egbertson MS Vocca JP Huff JR Felock PJ Witmer MV Stillmock KA Danovich R Grobler J Miller MD Espeseth AS Jin L Chen I Lin JH Kassahun K Ellis JD Wong BK Xu Wei Pearson PG Schleif WA Cortese R Emini E Summa V Holloway K Young SD Coffin JM A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase Proc Natl Acad Sci USA 2004, 101:11233-11238 509174 15277684
32. Egbertson MS Moritz HM Melamed JY Han W Perlow DS Kuo MS Embrey M Vacca JP Zrada MM Cortes AR Wallace A Leonard Y Hazuda DJ Miller MD Felock PJ Stillmock KA Witmer MV Schleif W Gabryelski LJ Moyer G Ellis JD Jin L Xu W Braun MP Kassahun K Tsou NN Young SD A potent and orally active HIV-1 integrase inhibitor Bioorg Med Chem Lett 2007, 17:1392-1398 17194584
33. Shimura K Kodama E Sakagami Y Matsuzaki Y Watanabe W Yamataka K Watanabe Y Ohata Y Doi S Sato M Kano M Ikeda S Matsuoka M Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137) J Virol 2007 2224569 17977962
34. Grinsztejn B Nguyen BY Katlama C Gatell JM Lazzarin A Vittecoq D Gonzalez CJ Chen J Harvey CM Isaacs RD Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial Lancet 2007, 369:1261-1269 17434401
35. Markowitz M Nguyen BY Gotuzzo E Mendo F Ratanasuwan W Kovacs C Prada G Morales-Ramirez JO Crumpacker CS Isaacs RD Gilde LR Wan H Miller MD Wenning LA Teppler H Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study J Acquir Immune Defic Syndr 2007, 46:125-133 17721395
36. Steigbigel R Kumar P Eron J Schechter M Markowitz M Loutfy MR Zhao J Isaacs R Nguyen-Ba N Teppler H Results of the BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518 a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus 14th Conference on Retroviruses and Opportunistic Infections 2007:104
37. Cooper D Gatell AJ Rockstroh J Katlama C Yeni P Lazzarin A Chen J Isaacs R Teppler H Nguyen BY Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518 a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105aLB] 14th Conference on Retroviruses and Opportunistic Infections 2007:103
38. DeJesus E Berger D Markowitz M Cohen C Hawkins T Ruane P Elion R Farthing C Zhong L Cheng AK Mccoll D Kearney BP Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients J Acquir Immune Defic Syndr 2006, 43:1-5 16936557
39. Zolopa A Mullen M Berger D Ruane P Hawkins T Zhong L Chuck S Enejosa J Kearnery B Cheng A The HIV-1 integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients [abstract 143LB] 14th Conference on Retroviruses and Opportunistic Infections 2007
40. Grobler JA Stillmock K Hu B Witmer M Felock P Espeseth AS Wolfe A Egbertson M Bourgeois M Melamed J Wai JS Young S Vacca J Hazuda DJ Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes Proc Natl Acad Sci USA 2002, 99:6661-6666 124459 11997448
41. Fikkert V Hombrouck A Van Remoortel B De Maeyer M Pannecouque C De Clercq E Debyser Z Witvrouw M Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360 AIDS 2004, 18:2019-2028 15577623
42. Hombrouck A Voet A Van Remoortel B Desadeleer C De Maeyer M Debyser Z Witvrouw M Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137 Antimicrob Agents Chemother 2008, 52:2069-2078 18378713
43. Witmer M Danovich R Ke Y Day A Gabryelski L Ecto L McKenna P Miller M Hazuda D In vitro resistance selection studies using raltegravir: A novel inhibitor of HIV-1 integrase 8th Annual Symposium on Antiviral Drug Resistance, Richmond VA, November 11 - 14, 2007 2007
44. Malet I Delelis O Valantin MA Montes B Soulie C Wirden M Tchertanov L Peytavin G Reynes J Mouscadet JF Katlama C Calvez V Marcelin AG Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrob Agents Chemother 2008, 52:1351-1358 2292515 18227187
45. Miller MD Danovich RM Ke Y Witmer MV Zhao J Harvey C Nguyen BY Hazuda DJ Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltebravir: Results from P005, a phase 2 study in treatment expreienced patients [abstract 6] Antivir Ther 2008, 13(Suppl 3):A8
46. Goodman D Hluhanich R Waters J Margot NA Fransen S Gupta S Huang W Parkin N Borroto-Esoda K Svarovskaia ES Miller MD McColl DJ Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: A novel mutation L68V/I associates with E92Q and increases resistance [abstact 13] Antviral Ther 2008, 13(Suppl 3):A15
47. Hatano H Lampiris H Huang W Hoh R Gupta S Fransen S Martin JN Petropoulos CJ Deeks SG Virological and immunological outcomes in a cohort of patients failing integrase inhibitors [abstract 10] Antivir Ther 2008, 13(Suppl 3):A12
48. Katlama C Caby F Andrade R Schneider L Canestri A Ktorza N Tubiana R Valantin M Wirden M Mallet I Calvez V Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens [abstract 11] Antivir Ther 2008, 13(Suppl 3):A13
49. Da Silva D Pellgrin I Anies G Breilh D Wittkop L Morlat P Dupon M Neau D Pellegrin J Fleury H Masquelier B Mutational patterns in the HIV-1 integrase related to virological failures on raltegravir-containing regimens [abstract 12] Antivir Ther 2008, 13(Suppl 3):A14
50. Ceccherini-Silberstein F Armenia D D'Arrigo R Micheli V Fabeni L Meraviglia P Capetti a Zaccarelli M Trotta MP Narciso P Antinori A Perno CF Virological response and resistance in multi-experienced patients treated with raltegravir [abstract 18] Antivir Ther 2008, 13(Suppl 3):A20
51. Savarino A In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate Retrovirology 2007, 4:21 1847836 17374162
52. Fransen S Gupta S Danovich R Hazuda DJ Miller M Witmer M Petropoulos CJ Parkin N Huang W Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways [abstract 7] Antivir Ther 2008, 13(Suppl 3):A9
53. Ren C May S Miletti T Bedard J In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1 [abstract 1] Antivir Ther 2007, 12:S3
54. Kodama E Shimura K Sakagami Y Matsuzaki Y Watanabe W Yamataka K Sato M Kano M Ikeda S Matsuoka M In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137 ICAAC 2006
55. Low A Mohri H Markowitz M Frequency of naturally occurring polymorphisms associated with resistance to integrase inhibitors in a recently infected cohort [abstract 625] 14th Conference on Retroviruses and Opportunistic Infections 2007
56. Yerly S Hirschel B Gaille C Kaiser L Perrin L Natural polymorphism of HIV-1subtypes B and non-B integrase gene [abstract 626] 14th Conference on Retroviruses and Opportunistic Infections 2007
57. Smith P Holzmayer V Fang L Swanson P Hackett J Marlowe N Performance of prototype integrase genotyping reatents for analysis of diverse HIV-1 strains [abstract 881] 15th Conference on Retroviruses and Opportunistic Infections 2008
58. Ceccherini-Silberstein F Malet I Fabeni L Svicher V Gori C Dimonte S Bono S Artese A D'Arrigo R Katlama C Antinori A Monforte A Calvez V Marcelin AG Perno CF Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients [abstract 4] Antivir Ther 2007, 12:S6
59. Van Baelen K Clynhens M Rondelez E Van Eygen V Zegel Van den P Vermeiren H Vandenbroucke I Stuyver L Low level of baseline resistance to integrase inhibitors L731,988 and L870,810 in randomly selected subtype B and non-B HIV-1 strains [abstract 5] Antivir Ther 2008, 12:S7
60. Frahm N Linde C Brander C Identfication of HIV-derived, HLA class I restricted CTL epitopes: Insights into TCR repertoire, CTL escape and viral fitness HIV Molecular Immunology 2006/2007 Los Alamos: Los Alamos National Laboratory, Theoretical Biology and Biophysics Korbert BTBC, Haynes BF, Koup R, Moore JP, Walker BD, Watkins DI 2007 3-28